Worth Venture Partners LLC purchased a new stake in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in the fourth quarter, HoldingsChannel reports. The firm purchased 9,557 shares of the company’s stock, valued at approximately $436,000.

Several other hedge funds also recently made changes to their positions in the company. Mesirow Financial Investment Management Equity Management bought a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $14,671,000. Stonepine Capital Management LLC bought a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $14,089,000. Epoch Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares in the last quarter. BlackRock Inc. increased its stake in Pacira Pharmaceuticals by 9.2% during the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after purchasing an additional 294,494 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after purchasing an additional 211,982 shares in the last quarter.

In other news, CEO David M. Stack sold 58,885 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark A. Kronenfeld acquired 1,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was bought at an average cost of $41.60 per share, with a total value of $41,600.00. Following the acquisition, the director now owns 6,795 shares in the company, valued at approximately $282,672. The disclosure for this purchase can be found here. In the last three months, insiders sold 98,960 shares of company stock valued at $3,868,341. 6.60% of the stock is currently owned by insiders.

Pacira Pharmaceuticals Inc (NASDAQ PCRX) traded up $1.75 during midday trading on Thursday, hitting $38.15. The stock had a trading volume of 328,386 shares, compared to its average volume of 818,432. The firm has a market cap of $1,480.00, a P/E ratio of -28.74 and a beta of 2.20. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals Inc has a 12 month low of $29.81 and a 12 month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.20 EPS. equities analysts predict that Pacira Pharmaceuticals Inc will post -0.86 EPS for the current fiscal year.

A number of research firms recently issued reports on PCRX. Canaccord Genuity lowered their target price on Pacira Pharmaceuticals from $46.00 to $42.00 and set a “hold” rating for the company in a research note on Tuesday. BidaskClub downgraded Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, January 26th. Seaport Global Securities started coverage on Pacira Pharmaceuticals in a research report on Friday, January 19th. They set a “buy” rating and a $50.00 price target for the company. ValuEngine raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Zacks Investment Research downgraded Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average price target of $48.82.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/02/01/9557-shares-in-pacira-pharmaceuticals-inc-pcrx-purchased-by-worth-venture-partners-llc.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.